Cancer BiologybioRxivPreprint
A clinical-stage oncology compound selectively targets drug-resistant cancers
Kaitlin Long, Debanjan Bhattacharjee, Samuel H. Newman-Stonebraker…·Jason M. Sheltzer
This study reveals that PAC-1, a clinical-stage oncology compound, targets drug-resistant cancers by disrupting iron homeostasis and exploiting MDR1 expression to induce iron depletion.
DOI 10.1101/2025.11.26.690878